Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

作者：Gassanov Natig; Semmo Nasser; Semmo Mariam; Nia Amir M; Fuhr Uwe; Er Fikret^*

来源：European Journal of Clinical Pharmacology, 2011, 67(4): 333-346.

DOI：10.1007/s00228-011-1006-7

• Vasopressin
• Vaptans
• Hyponatremia
• Heart failure
• SIADH

Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.

• 出版日期2011-4